{
    "clinical_study": {
        "@rank": "90742", 
        "arm_group": {
            "arm_group_label": "Metformin and Flourouracil", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a phase II trial to evaluate efficacy and safety of Metformin and Fluorouracil in\n      patients with metastatic colorectal cancer (CRC) who have progressed after Oxaliplatin and\n      Irinotecan based chemotherapy."
        }, 
        "brief_title": "Metformin and 5-fluorouracil for Refractory Colorectal Cancer.", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Primary Outcomes Measures:\n\n      - Disease control Rate at 8 weeks according to RECIST 1.1 (Tumor response was defined as the\n      percentage of patients with complete response, partial response or stable disease as best\n      overall response).\n\n      Secondary Outcome Measures:\n\n        -  Progression-free Survival\n\n        -  Overall Survival\n\n        -  Adverse Events (assessed according to the Common Toxicity Criteria for Adverse Events\n           (CTCAE) version 4.0)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Histological diagnosis of metastatic colorectal adenocarcioma previously treated with\n             at least two lines of chemotherapy (oxaliplatin and irinotecan regimens) if mutated\n             KRAS or treated with at least 3 lines of chemotherapy (oxaliplatin, irinotecan and\n             cetuximab) if KRAS wild type.\n\n          -  Disease progression according to radiological or clinical assessment.\n\n          -  Measurable disease.\n\n          -  ECOG Performance 0-1.\n\n          -  Age above 16 years.\n\n          -  Normal organic function as defined for the following criteria:\n\n               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \u2264 2.5 times the\n                  upper normal limit of the local laboratory (LSN-LL);\n\n               -  Total serum bilirubin \u2264 2.0 x ULN-LL;\n\n               -  Absolute neutrophil count \u2265 1,500 / mm3;\n\n               -  Platelet count \u2265 100,000 / mm3;\n\n               -  Hemoglobin \u2265 8.0 g / dl;\n\n               -  Serum creatinine \u2264 1.5 x ULN-LL\n\n          -  Written informed consent before enrollment\n\n        Exclusion Criteria\n\n          -  Diabetic patients taking metformin.\n\n          -  Patients already treated with mTOR inhibitors.\n\n          -  Hypersensitivity to metformin, renal or hepatic impairment or other conditions that\n             predispose to lactic acidosis.\n\n          -  History of acute myocardial infarction in the last 6 months\n\n          -  Serious illness or psychiatric condition.\n\n          -  Current participation in other protocols with experimental drugs.\n\n          -  Suspicion of dihidropirimida dehydrogenase(DPD)deficiency.\n\n          -  Presence of active infection.\n\n          -  No ability to ingest food orally.\n\n          -  Patients with metastatic disease to CNS.\n\n          -  Patients who underwent major surgery in the last 4 weeks.\n\n          -  Patients who received chemotherapy in the last three weeks.\n\n          -  Patients who underwent radiotherapy in the last 2 weeks or who received radiotherapy\n             in the target lesion, if this is the only target lesion.\n\n          -  Patients using oral anticoagulation (warfarin).\n\n          -  Pregnant or lactating patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941953", 
            "org_study_id": "NP 273/12"
        }, 
        "intervention": {
            "arm_group_label": "Metformin and Flourouracil", 
            "description": "metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly", 
            "intervention_name": "Metformin and Fluorouracil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metformin", 
            "Metastatic Colorectal Cancer", 
            "Fluorouracil"
        ], 
        "lastchanged_date": "September 10, 2013", 
        "location": {
            "contact": {
                "email": "vamedabc@yahoo.com.br", 
                "last_name": "Vanessa C Miranda, MD", 
                "phone": "+551138932686"
            }, 
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "zip": "01246-000"
                }, 
                "name": "Instituto Do Cancer Do Estado de S\u00e3o Paulo"
            }, 
            "investigator": {
                "last_name": "Vanessa C Miranda, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Metformin and 5-fluorouracil in Patients With Advanced Colorectal Cancer Previously Treated With Oxaliplatin and Irinotecan Based Chemotherapy.", 
        "overall_contact": {
            "last_name": "Vanessa C Miranda, MD", 
            "phone": "+551138932686"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease Control Rate according to RECIST 1.1", 
            "safety_issue": "No", 
            "time_frame": "From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 8 week intervals"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941953"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
            "investigator_full_name": "Vanessa C Miranda", 
            "investigator_title": "Fellow in Clinical Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "defined as time from randomization to death from any cause, or even radiological detection/or clinical of disease progression, increased CEA will not be considered isolated progression.", 
                "measure": "Progression-free Survival", 
                "safety_issue": "No", 
                "time_frame": "From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 4 week intervals."
            }, 
            {
                "description": "defined as time from first dose of treatment until death, with date of last visit being considered censorship", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 4 week intervals"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 4 week intervals."
            }
        ], 
        "source": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}